Braveheart Bio, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
BRVE$19.62+0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
Condensed Balance Sheets (unaudited)
(in thousands, except share and par value data)
| As ofSeptember 30,2026 | As ofDecember 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $121,291 | $89,161 |
| Prepaid expenses and other current assets | 10,302 | 119 |
| Short-term investments | 227,981 | — |
| Total current assets | 359,574 | 89,280 |
| Property and equipment, net | 20 | — |
| Operating lease right-of-use assets | 510 | — |
| Other long-term assets | 98 | 70 |
| Long-term investments | 154,248 | — |
| Total assets | $514,450 | $89,350 |
| Liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) | ||
| Current liabilities | ||
| Accounts payable (includes related party amounts of $13 and $73, respectively) | $1,975 | $1,058 |
| Accrued expenses (includes related party amounts of $1,431 and $3,272, respectively) | 8,138 | 4,184 |
| Other current liabilities | 6,145 | — |
| Current portion of lease liabilities | 415 | — |
| Total current liabilities | 16,673 | 5,242 |
| Lease liabilities, net of current portion | 100 | — |
| Other long-term liabilities | 75 | 91 |
| Total liabilities | 16,848 | 5,333 |
| Commitments and contingencies (Note 7) | ||
| Series A redeemable convertible preferred stock, $0.0001 par value; zero and 185,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; zero and 125,000,000 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively; $0 and $125,000 liquidation preference at September 30, 2026 and December 31, 2025, respectively | — | 124,214 |
| Nonvoting Series A redeemable convertible preferred stock, $0.0001 par value; zero and 32,500,000 shares authorized, issued and outstanding at September 30, 2026 and December 31, 2025, respectively; $0 and $32,500 liquidation preference at September 30, 2026 and December 31, 2025, respectively | — | 25,675 |
| Stockholders’ equity (deficit) | ||
| Undesignated preferred stock, $0.0001 par value; 10,000,000 and zero shares authorized at September 30, 2026 and December 31, 2025, respectively; zero shares issued and outstanding at September 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 500,000,000 and 335,500,000 (303,000,000 voting and 32,500,000 nonvoting) shares authorized at September 30, 2026 and December 31, 2025, respectively; 89,867,737 and 15,943,937 shares issued at September 30, 2026 and December 31, 2025, respectively; and 82,069,077 and 6,685,088 shares outstanding at September 30, 2026 and December 31, 2025, respectively | 8 | 1 |
|---|---|---|
| Accumulated other comprehensive loss | (718) | — |
| Additional paid-in capital | 620,714 | 179 |
| Accumulated deficit | (122,402) | (66,052) |
| Total stockholders’ equity (deficit) | 497,602 | (65,872) |
| Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) | $514,450 | $89,350 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.